Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a sell rating to a hold rating in a research report released on Friday, Zacks.com reports.

According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “

A number of other research firms have also commented on ARDS. Maxim Group reiterated a buy rating and issued a $25.00 price objective on shares of Aridis Pharmaceuticals in a research note on Monday, April 1st. Northland Securities reiterated a buy rating and issued a $40.00 price objective on shares of Aridis Pharmaceuticals in a research note on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Aridis Pharmaceuticals has an average rating of Buy and an average target price of $27.50.

Aridis Pharmaceuticals stock opened at $11.12 on Friday. The business has a 50-day simple moving average of $9.05. The company has a market capitalization of $87.18 million and a price-to-earnings ratio of -1.59. Aridis Pharmaceuticals has a 52 week low of $6.91 and a 52 week high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.12). The business had revenue of $1.02 million during the quarter. Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%. As a group, equities analysts expect that Aridis Pharmaceuticals will post -3.11 EPS for the current year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Read More: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.